Observational studyBreast (Edinburgh, Scotland)2026
Chemotherapy is associated with differential survival outcomes in apocrine carcinoma: A nationwide cohort study from the Japanese National Clinical Database-Breast Cancer Registry.
Observational study in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApocrine carcinoma (AC) is a rare breast cancer subtype, and the benefit of adjuvant chemotherapy for early-stage disease remains uncertain. Prior studies suggest limited chemotherapy responsiveness in triple-negative AC (TNAC), whereas evidence in pure HER2-positive AC is scarce. This study described outcomes in AC using a national registry and examined outcomes by systemic treatment across subtypes.
methodsUsing the Japanese National Clinical Database-Breast Cancer Registry, we identified 2817 patients with AC from 2004 to 2019. Patients were categorized as pure HER2 AC or TNAC. The primary endpoint was distant metastasis-free survival (DMFS); overall survival (OS) was also assessed. Survival outcomes were analyzed using Kaplan-Meier and Cox models.
resultsAdjuvant chemotherapy was associated with longer DMFS in the overall cohort (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.51-0.96). Subtype-specific analyses showed significantly longer DMFS (HR, 0.26; 95%CI, 0.12-0.57) and OS (HR, 0.18; 95%CI, 0.06-0.57) in patients who received chemotherapy in the pure HER2 AC group; 5-year DMFS was 96.1% with chemotherapy versus 86.8% without. In contrast, no significant association between chemotherapy and DMFS (HR, 0.84; 95%CI, 0.60-1.18) or OS (HR, 0.84; 95%CI, 0.55-1.28) was observed in TNAC, with similar 5-year DMFS with and without chemotherapy (91.1% vs. 89.2%).
conclusionIn this large population-based cohort of early-stage AC, the association between adjuvant chemotherapy and outcomes differed by subtype. Chemotherapy was associated with better outcomes in pure HER2 AC, whereas no clear association was observed in TNAC. These findings suggest that treatment strategies for AC may need to consider subtype-specific differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.